LSDEarly Phase 1MESA-DNCT07017478
Mood Effects of Serotonin Agonists: Depression
A Early Phase 1 study testing LSD in people with LSD and Major Depressive Disorder, run by University of Chicago at 1 site in United States.
Trial summary
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- LSD, Major Depressive Disorder, Depression
- What is being tested?
- LSD
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 41 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jun 2025to 1 Jun 2026
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- English Fluency
- high school education or higher
- BMI between 19-30 kg/m2
Who cannot join
- individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease)
- high blood pressure (>140/90)
- current suicidal ideation or suicide attempt in past 12 months
- past year severe substance use disorder
- personal or first-degree relative with history of psychosis
- currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks)
Show all 10Show fewer
- active panic disorder
- severe obsessive-compulsive disorder
- severe post-traumatic stress disorder
- women who are pregnant or planning to become pregnant
Trial locations and contacts
1 site in 1 country.
About this study
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.
Read the detailed description
Depression is one of the leading mental health disorders in the U.S, with an estimated 21 million adults having at least one major depressive episode in the past year. Existing antidepressant medications have limited efficacy, undesirable side effects and can take weeks to months to provide relief of symptoms. Compounds that modulate serotonin 2A receptor signaling have potential to elicit rapid antidepressant effects, and one promising example of these compounds is lysergic acid diethylamide (LSD). There are widespread reports that very low doses of LSD improve mood and energy without producing hallucinogenic effects. Yet, these effects have not been rigorously tested under blinded, placebo-controlled conditions. There is an urgent need for controlled studies to assess the potential efficacy and the mechanisms that mediate any therapeutic effects.
In a preliminary double-blind, placebo-controlled study, the investigators found that depressed individuals reported acute mood enhancing effects after a single low dose of LSD, as well as improvements in anhedonia and sleep disturbance related symptoms, for as long as two days after the dose (preliminary data). The mechanisms underlying these effects are not known. While the acute mood enhancing effects may be due to direct actions of the drug at serotonin 2A receptors, animal models suggest that the sustained antidepressant-like effects of LSD are mediated by enhanced neural plasticity. In healthy humans, low doses of LSD produce sustained neurophysiological changes detected via EEG and on sleep measures, some of which may be related to antidepressant effects. In animal models, LSD produces long-lasting antidepressant-like responses as well as increased synaptic and dendritic growth in cortical regions days after drug exposure. Notably, these changes in structural plasticity are dependent on brain derived neurotrophic factor (BDNF), a protein that peaks after 24 hours in animal models.
In the current study the investigators will examine acute and delayed improvements in mood following a single low dose of LSD, in individuals with major depressive disorder (MDD). The investigators will examine the mechanisms underlying these antidepressant effects by assessing drug-induced neurophysiological changes using depression-sensitive behavioral tasks, EEG, and changes in sleep quality and architecture.
- Conditions
- LSD, Major Depressive Disorder, Depression
- Being tested
- LSD, Placebo
- Medical subject headings
- Depressive Disorder, Major, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LSDDrug
The serotonin 2A receptor agonist LSD
PlaceboDrug
Distilled water
| Study group | Role | What they receive |
|---|---|---|
| placebo | Placebo comparator | distilled water (0.26 mL) Receives: Drug: Placebo |
| LSD (26 micrograms) | Experimental | LSD tartrate in tasteless solution (0.26 mL) Receives: Drug: LSD |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acute Mood Measures
Acute (Profile of Mood States scale ratings from 0-60).
Measured: Peak change (~2 hours post-drug) from pre-drug baseline
Acute Mood Measures
Acute (Visual Analog Scale questionnaires, scale ratings from 0-100).
Measured: Peak change (~2 hours post-drug) from pre-drug baseline
Delayed Mood Measures
Delayed depressed mood measures (Beck Depression Inventory [score range: 0-63, higher scores greater symptoms severity] and Inventory of depression and anxiety symptoms [score range: 0-48, higher scores increased severity])
Measured: Change from baseline (orientation) to 48-hour followup
Effort expenditure for reward (EEFRT) Behavioral Task Performance
Effort Expenditure for Reward Task
Measured: 2 hours post-drug administration
Sleep Quality
Electroencephalogram (EEG) power to assess time spent in Rapid Eye Movemeent [REM] and slow wave sleep
Measured: Change from baseline (pre-drug) to Night 0, 1, and 2 post-drug
Sleep Quality
subjective measures of sleep function (Karolinska sleep log)
Measured: Change from baseline (pre-drug) to Night 0, 1, and 2 post-drug
Secondary outcomes (4)
Self-reported feelings of connection using Likert scale conversation questionnaires
ratings of connectedness
Measured: Collected at the end of the session, 270 minutes post-drug administration
Natural Language Processing using large language model
Differences in speech content across drug conditions will be assessed using a sentiment analysis score
Measured: during 45 minute conversation, occurring 150 min after drug administration
Facial expression analysis using HUMEAI software for positive and negative affect
Changes in emotional facial expressions during conversations across drug conditions (positive, negative affect)
Measured: during 45 minute conversation, occurring 150 min after drug administration
Self-Esteem implicit association test
Changes in Self-esteem IAT scores across drug conditions
Measured: 2 hours post drug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2025
- Study start9 Jun 2025
- Primary completion1 Jun 2026
- Study completion1 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for LSDStudies of the same condition, open and under way.
- More trials run by University of ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Responsible party
- Sponsor
- Investigators
- Hanna Molla, Principal investigator, University of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07017478
- Sponsor's protocol ID
- IRB24-1947
- Other IDs
- 5R01DA002812-35
- Acronym
- MESA-D
- Status last verified
- Jul 2026
- First submitted
- 22 Apr 2025
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Duan W, Cao D, Wang S, Cheng J. Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. Chem Rev. 2024 Jan 10;124(1):124-163. doi: 10.1021/acs.chemrev.3c00375. Epub 2023 Nov 30.
PubMed 38033123Husain MI, Ledwos N, Fellows E, Baer J, Rosenblat JD, Blumberger DM, Mulsant BH, Castle DJ. Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? Front Psychiatry. 2023 Feb 10;13:1076459. doi: 10.3389/fpsyt.2022.1076459. eCollection 2022.
PubMed 36844032Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, Lipsitz O, Gill H, Subramaniapillai M, Mansur RB, Lin K, Ho R, Rosenblat JD, Castle D, McIntyre RS. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. 2022 Jan;36(1):17-30. doi: 10.1007/s40263-021-00877-y. Epub 2021 Nov 17.
PubMed 34791625Murphy RJ, Muthukumaraswamy S, de Wit H. Microdosing Psychedelics: Current Evidence From Controlled Studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5):500-511. doi: 10.1016/j.bpsc.2024.01.002. Epub 2024 Jan 26.
PubMed 38280630Walsh CA, Gorfinkel L, Shmulewitz D, Stohl M, Hasin DS. Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA Psychiatry. 2024 Jan 1;81(1):89-96. doi: 10.1001/jamapsychiatry.2023.3867.
PubMed 37819655Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018 Jun 12;23(11):3170-3182. doi: 10.1016/j.celrep.2018.05.022.
PubMed 29898390Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsila LV, Sakson S, Cannarozzo C, Diniz CRAF, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Ohman T, Rog T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castren E. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023 Jun;26(6):1032-1041. doi: 10.1038/s41593-023-01316-5. Epub 2023 Jun 5.
PubMed 37280397Allen N, Jeremiah A, Murphy R, Sumner R, Forsyth A, Hoeh N, Menkes DB, Evans W, Muthukumaraswamy S, Sundram F, Roop P. LSD increases sleep duration the night after microdosing. Transl Psychiatry. 2024 Apr 15;14(1):191. doi: 10.1038/s41398-024-02900-4.
PubMed 38622150Hutten NRPW, Quaedflieg CWEM, Mason NL, Theunissen EL, Liechti ME, Duthaler U, Kuypers KPC, Bonnelle V, Feilding A, Ramaekers JG. Inter-individual variability in neural response to low doses of LSD. Transl Psychiatry. 2024 Jul 15;14(1):288. doi: 10.1038/s41398-024-03013-8.
PubMed 39009578Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019 Nov 15;86(10):792-800. doi: 10.1016/j.biopsych.2019.05.019. Epub 2019 Jun 3.
PubMed 31331617
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mood Effects of Serotonin Agonists: Depression
- ClinicalTrials.gov ID
- NCT07017478
- Acronym / sponsor ID
- MESA-D / IRB24-1947
- Conditions
- LSD, Major Depressive Disorder, Depression
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- University of ChicagoUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Study start
- 9 Jun 2025 (actual)
- Primary completion
- 1 Jun 2026 (actual)
- Study completion
- 1 Jun 2026 (actual)
- First posted
- 12 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.
Detailed description
Depression is one of the leading mental health disorders in the U.S, with an estimated 21 million adults having at least one major depressive episode in the past year. Existing antidepressant medications have limited efficacy, undesirable side effects and can take weeks to months to provide relief of symptoms. Compounds that modulate serotonin 2A receptor signaling have potential to elicit rapid antidepressant effects, and one promising example of these compounds is lysergic acid diethylamide (LSD). There are widespread reports that very low doses of LSD improve mood and energy without producing hallucinogenic effects. Yet, these effects have not been rigorously tested under blinded, placebo-controlled conditions. There is an urgent need for controlled studies to assess the potential efficacy and the mechanisms that mediate any therapeutic effects.
In a preliminary double-blind, placebo-controlled study, the investigators found that depressed individuals reported acute mood enhancing effects after a single low dose of LSD, as well as improvements in anhedonia and sleep disturbance related symptoms, for as long as two days after the dose (preliminary data). The mechanisms underlying these effects are not known. While the acute mood enhancing effects may be due to direct actions of the drug at serotonin 2A receptors, animal models suggest that the sustained antidepressant-like effects of LSD are mediated by enhanced neural plasticity. In healthy humans, low doses of LSD produce sustained neurophysiological changes detected via EEG and on sleep measures, some of which may be related to antidepressant effects. In animal models, LSD produces long-lasting antidepressant-like responses as well as increased synaptic and dendritic growth in cortical regions days after drug exposure. Notably, these changes in structural plasticity are dependent on brain derived neurotrophic factor (BDNF), a protein that peaks after 24 hours in animal models.
In the current study the investigators will examine acute and delayed improvements in mood following a single low dose of LSD, in individuals with major depressive disorder (MDD). The investigators will examine the mechanisms underlying these antidepressant effects by assessing drug-induced neurophysiological changes using depression-sensitive behavioral tasks, EEG, and changes in sleep quality and architecture.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| placebo | Placebo comparator | Drug: Placebodistilled water (0.26 mL) |
| LSD (26 micrograms) | Experimental | Drug: LSDLSD tartrate in tasteless solution (0.26 mL) |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- English Fluency
- high school education or higher
- BMI between 19-30 kg/m2
Key exclusion criteria (10 listed)
- individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease)
- high blood pressure (>140/90)
- current suicidal ideation or suicide attempt in past 12 months
- past year severe substance use disorder
- personal or first-degree relative with history of psychosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LSDThe serotonin 2A receptor agonist LSD | Drug | LSD (26 micrograms) |
| PlaceboDistilled water | Drug | placebo |
Primary outcome
Acute Mood Measures
Time frame: Peak change (~2 hours post-drug) from pre-drug baseline
Acute (Profile of Mood States scale ratings from 0-60).
Acute Mood Measures
Time frame: Peak change (~2 hours post-drug) from pre-drug baseline
Acute (Visual Analog Scale questionnaires, scale ratings from 0-100).
Delayed Mood Measures
Time frame: Change from baseline (orientation) to 48-hour followup
Delayed depressed mood measures (Beck Depression Inventory [score range: 0-63, higher scores greater symptoms severity] and Inventory of depression and anxiety symptoms [score range: 0-48, higher scores increased severity])
Effort expenditure for reward (EEFRT) Behavioral Task Performance
Time frame: 2 hours post-drug administration
Effort Expenditure for Reward Task
Sleep Quality
Time frame: Change from baseline (pre-drug) to Night 0, 1, and 2 post-drug
Electroencephalogram (EEG) power to assess time spent in Rapid Eye Movemeent [REM] and slow wave sleep
Sleep Quality
Time frame: Change from baseline (pre-drug) to Night 0, 1, and 2 post-drug
subjective measures of sleep function (Karolinska sleep log)
4 secondary outcomes
Self-reported feelings of connection using Likert scale conversation questionnaires
Time frame: Collected at the end of the session, 270 minutes post-drug administration
Natural Language Processing using large language model
Time frame: during 45 minute conversation, occurring 150 min after drug administration
Facial expression analysis using HUMEAI software for positive and negative affect
Time frame: during 45 minute conversation, occurring 150 min after drug administration
Self-Esteem implicit association test
Time frame: 2 hours post drug
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Background: PubMed 38033123Duan W, Cao D, Wang S, Cheng J. Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. Chem Rev. 2024 Jan 10;124(1):124-163. doi: 10.1021/acs.chemrev.3c00375. Epub 2023 Nov 30.
- Background: PubMed 36844032Husain MI, Ledwos N, Fellows E, Baer J, Rosenblat JD, Blumberger DM, Mulsant BH, Castle DJ. Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? Front Psychiatry. 2023 Feb 10;13:1076459. doi: 10.3389/fpsyt.2022.1076459. eCollection 2022.
- Background: PubMed 34791625Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, Lipsitz O, Gill H, Subramaniapillai M, Mansur RB, Lin K, Ho R, Rosenblat JD, Castle D, McIntyre RS. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. 2022 Jan;36(1):17-30. doi: 10.1007/s40263-021-00877-y. Epub 2021 Nov 17.
- Background: PubMed 38280630Murphy RJ, Muthukumaraswamy S, de Wit H. Microdosing Psychedelics: Current Evidence From Controlled Studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5):500-511. doi: 10.1016/j.bpsc.2024.01.002. Epub 2024 Jan 26.
- Background: PubMed 37819655Walsh CA, Gorfinkel L, Shmulewitz D, Stohl M, Hasin DS. Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA Psychiatry. 2024 Jan 1;81(1):89-96. doi: 10.1001/jamapsychiatry.2023.3867.
- Background: PubMed 29898390Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018 Jun 12;23(11):3170-3182. doi: 10.1016/j.celrep.2018.05.022.
- Background: PubMed 37280397Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsila LV, Sakson S, Cannarozzo C, Diniz CRAF, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Ohman T, Rog T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castren E. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023 Jun;26(6):1032-1041. doi: 10.1038/s41593-023-01316-5. Epub 2023 Jun 5.
- Background: PubMed 38622150Allen N, Jeremiah A, Murphy R, Sumner R, Forsyth A, Hoeh N, Menkes DB, Evans W, Muthukumaraswamy S, Sundram F, Roop P. LSD increases sleep duration the night after microdosing. Transl Psychiatry. 2024 Apr 15;14(1):191. doi: 10.1038/s41398-024-02900-4.
- Background: PubMed 39009578Hutten NRPW, Quaedflieg CWEM, Mason NL, Theunissen EL, Liechti ME, Duthaler U, Kuypers KPC, Bonnelle V, Feilding A, Ramaekers JG. Inter-individual variability in neural response to low doses of LSD. Transl Psychiatry. 2024 Jul 15;14(1):288. doi: 10.1038/s41398-024-03013-8.
- Background: PubMed 31331617Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019 Nov 15;86(10):792-800. doi: 10.1016/j.biopsych.2019.05.019. Epub 2019 Jun 3.
- Husain et al., 2022Link provided by the sponsor.
- Ling et al., 2022Link provided by the sponsor.
- Murphy et al., 2024Link provided by the sponsor.
- Ly et al., 2018Link provided by the sponsor.
- Moliner et al., 2023Link provided by the sponsor.
- Allen et al., 2024Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for LSD
Active, not recruitingPhase 2
Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache
Cluster Headache
Not yet recruitingPhase 1
Shortened LSD Intervention for Major Depressive Disorder
Major Depression Moderate, Major Depression Severe
RecruitingPhase 2
LSD Treatment for Persons With Alcohol Use Disorder
Alcohol Use Disorder (AUD)
Not yet recruitingPhase 2
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)
Lysosomal Storage Disorders, Sandhoff Disease
RecruitingPhase 1
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hanna Molla principal investigator
University of Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing LSD in people with LSD and Major Depressive Disorder, run by University of Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acute Mood Measures (time frame: Peak change (~2 hours post-drug) from pre-drug baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07017478, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.